Advance Your Polymyositis or Dermatomyositis Interventions with Worldwide Clinical Trials

The muscle weakness that characterizes polymyositis or the muscle weakness and skin outbreaks that characterize dermatomyositis can be debilitating for the individuals affected by these conditions. Polymyositis and dermatomyositis are related autoimmune rheumatic disorders whose causes are not well understood but whose severity has generally proven to lessen in response to the application of corticosteroids. Although these treatments can clear up the skin conditions and help individuals regain muscle strength, they also can create other problems – ranging from high blood sugar to glaucoma and osteoporosis, which in turn require other interventions involving the use of immunosuppressive drugs and/or immune globulin.

Is there a better way to combat polymyositis or dermatomyositis? If you’re working on a new way to combat these disorders, you’ll need to prove the efficacy and safety of your approach by passing it through the rigors of clinical trials.

That’s where Worldwide Clinical Trials can help power your research forward. With more than 30 years of experience supporting research in oncology and immune-mediated inflammatory disorders (IMID), Worldwide is an internationally acclaimed expert in clinical trial management. We offer full-service support for Phase I-Phase IV clinical trials, as well as real-world evidence studies, that can help you understand the effects of your work over both the short and long term. We have a global footprint, with connections to facilities and clinicians in more than 60 countries. We also have the experience and the expertise to ensure that your trials – even when they involve rare disorders – will have committed participants to help you prove your case.

Are you already planning your clinical trials? Call Worldwide to learn how we can help.